Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia.

Authors

Nisha Narayanan
Jennifer Marvin-Peek
Mohamad K Abouelnaaj
Dhabya Majid
Bofei Wang
Brandon D Brown
Yihua Qiu
Steven M Kornblau
Hussein A Abbas

Publication Date

7-5-2024

Journal

Journal of Proteome Research

Abstract

Asparaginase-based therapy is a cornerstone in acute lymphoblastic leukemia (ALL) treatment, capitalizing on the methylation status of the asparagine synthetase (ASNS) gene, which renders ALL cells reliant on extracellular asparagine. Contrastingly, ASNS expression in acute myeloid leukemia (AML) has not been thoroughly investigated, despite studies suggesting that AML with chromosome 7/7q deletions might have reduced ASNS levels. Here, we leverage reverse phase protein arrays to measure ASNS expression in 810 AML patients and assess its impact on outcomes. We find that AML with inv(16) has the lowest overall ASNS expression. While AML with deletion 7/7q had ASNS levels slightly lower than those of AML without deletion 7/7q, this observation was not significant. Low ASNS expression correlated with improved overall survival (46 versus 54 weeks, respectively,

Keywords

Humans, Leukemia, Myeloid, Acute, Aspartate-Ammonia Ligase, Female, Proteomics, Male, Middle Aged, Adult, Aged, Chromosome Deletion, Protein Array Analysis, Asparaginase, Chromosomes, Human, Pair 7, Young Adult, Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor

Comments

Supplementary Materials

PMID: 38829961